Arenillas Juan F, Alvarez-Sabín José, Montaner Joan, Rosell Anna, Molina Carlos A, Rovira Alex, Ribó Marc, Sánchez Esther, Quintana Manuel
Neurovascular Unit and Neurovascular Research Laboratory, Department of Neurology, Vall d'Hebron Hospital, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Stroke. 2005 Jan;36(1):92-7. doi: 10.1161/01.STR.0000149617.65372.5d. Epub 2004 Nov 18.
Angiogenesis may be beneficial in chronic myocardial and limb ischemia, but its role in intracranial atherosclerosis remains unknown. We aimed to investigate the relationship between the pro-angiogenic vascular endothelial growth factor (VEGF) and the anti-angiogenic endostatin, and the extent and risk of recurrence of symptomatic intracranial atherosclerosis.
Of a total of 94 consecutive patients with symptomatic intracranial stenoses, 40 fulfilled all inclusion criteria. Intracranial stenoses were confirmed by magnetic resonance angiography. Magnetic resonance imaging (MRI) including diffusion-weighted sequences was conducted. Plasmatic VEGF and endostatin were determined from blood samples obtained 3 months after stroke onset, and patients were followed-up thereafter.
A total of 144 intracranial stenoses were confirmed (median number per patient=3). Endostatin/VEGF ratio gradually augmented with the increasing number of intracranial stenoses (r=0.35, P=0.02). Diabetes mellitus (OR, 6.04; CI, 1.1 to 32.2; P=0.03) and a higher endostatin/VEGF ratio (OR, 15.7; CI, 2.2 to 112.3; P=0.006) were independently associated with a greater extent of intracranial atherosclerosis. During a median follow-up of 13 months, 8 patients (20%) experienced a new cerebral ischemic event. A higher baseline endostatin concentration was an independent predictor of new events (hazard ratio, 7.24; CI, 1.6 to 33.8; P=0.011) in a Cox regression model after adjustment for age, sex, number of stenotic vessels, and risk factors. Patients with a higher endostatin level had a lower survival free of new events (P=0.01, log-rank test).
A predominance of the inhibitor endostatin within the endogenous angiogenic response is associated with a greater extent and risk of recurrence of symptomatic intracranial atherosclerosis, suggesting that angiogenesis may be beneficial in this condition.
血管生成在慢性心肌和肢体缺血中可能有益,但它在颅内动脉粥样硬化中的作用尚不清楚。我们旨在研究促血管生成的血管内皮生长因子(VEGF)与抗血管生成的内皮抑素之间的关系,以及症状性颅内动脉粥样硬化的复发程度和风险。
在连续94例有症状性颅内狭窄的患者中,40例符合所有纳入标准。颅内狭窄通过磁共振血管造影确诊。进行了包括弥散加权序列在内的磁共振成像(MRI)检查。在卒中发病3个月后采集血样测定血浆VEGF和内皮抑素,并对患者进行随访。
共确诊144处颅内狭窄(每位患者的中位数为3处)。内皮抑素/VEGF比值随着颅内狭窄数量的增加而逐渐升高(r=0.35,P=0.02)。糖尿病(OR,6.04;CI,1.1至32.2;P=0.03)和较高的内皮抑素/VEGF比值(OR,15.7;CI,2.2至112.3;P=0.006)与颅内动脉粥样硬化程度较大独立相关。在中位随访13个月期间,8例患者(20%)发生了新的脑缺血事件。在调整年龄、性别、狭窄血管数量和危险因素后,较高的基线内皮抑素浓度是Cox回归模型中新事件的独立预测因子(风险比,7.24;CI,1.6至33.8;P=0.011)。内皮抑素水平较高的患者无新事件生存时间较短(P=0.01,对数秩检验)。
内源性血管生成反应中抑制剂内皮抑素占优势与症状性颅内动脉粥样硬化的程度较大和复发风险相关,提示血管生成在这种情况下可能有益。